VALENCIA, Calif., May 06, 2020 (GLOBE NEWSWIRE) — SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA)?to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA).